Literature DB >> 11024150

Impairment of human immunodeficiency virus type 1 (HIV-1) entry into Jurkat T cells by constitutive expression of the HIV-1 vpr protein: role of CD4 down-modulation.

L Conti1, B Varano, M C Gauzzi, P Matarrese, M Federico, W Malorni, F Belardelli, S Gessani.   

Abstract

Jurkat T-cell clones, stably expressing the human immunodeficiency virus type 1 (HIV-1) Vpr protein, exhibited an impaired susceptibility to HIV-1 infection. A marked down-modulation of surface CD4 receptors was detected in Vpr-expressing clones with respect to control cells. Likewise, a reduced CD4 expression was also observed in parental Jurkat cells infected with wild-type but not with Vpr-mutant HIV-1. Notably, Vpr-expressing clones were fully susceptible to infection with a vesicular stomatitis virus G protein-pseudotyped HIV-1 virus, indicating that a block at the level of viral entry was responsible for the inhibition of viral replication. The effect exerted by Vpr on HIV replication and CD4 expression suggests that this protein can regulate both the establishment of a productive HIV-1 infection and CD4-mediated T-cell functions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11024150      PMCID: PMC102060          DOI: 10.1128/jvi.74.21.10207-10211.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  The human immunodeficiency virus type 2 vpr gene is essential for productive infection of human macrophages.

Authors:  N Hattori; F Michaels; K Fargnoli; L Marcon; R C Gallo; G Franchini
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Viral protein R of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells.

Authors:  D Dedera; W Hu; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

3.  Identification of HIV-1 vpr product and function.

Authors:  E A Cohen; E F Terwilliger; Y Jalinoos; J Proulx; J G Sodroski; W A Haseltine
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

4.  Mutational analysis of the human immunodeficiency virus vpr open reading frame.

Authors:  K Ogawa; R Shibata; T Kiyomasu; I Higuchi; Y Kishida; A Ishimoto; A Adachi
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection.

Authors:  M Hrimech; X J Yao; F Bachand; N Rougeau; E A Cohen
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  Identification and localization of vpr gene product of human immunodeficiency virus type 1.

Authors:  A Sato; H Igarashi; A Adachi; M Hayami
Journal:  Virus Genes       Date:  1990-12       Impact factor: 2.332

7.  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

Authors:  J A Zack; S J Arrigo; S R Weitsman; A S Go; A Haislip; I S Chen
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

8.  Antisense phosphorothioate oligodeoxynucleotides targeted to the vpr gene inhibit human immunodeficiency virus type 1 replication in primary human macrophages.

Authors:  C Balotta; P Lusso; R Crowley; R C Gallo; G Franchini
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  Envelope glycoprotein of HIV induces interference and cytolysis resistance in CD4+ cells: mechanism for persistence in AIDS.

Authors:  M Stevenson; C Meier; A M Mann; N Chapman; A Wasiak
Journal:  Cell       Date:  1988-05-06       Impact factor: 66.850

10.  The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore.

Authors:  E Jacotot; L Ravagnan; M Loeffler; K F Ferri; H L Vieira; N Zamzami; P Costantini; S Druillennec; J Hoebeke; J P Briand; T Irinopoulou; E Daugas; S A Susin; D Cointe; Z H Xie; J C Reed; B P Roques; G Kroemer
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

View more
  2 in total

1.  Human immunodeficiency virus type 1 Vpr protein does not modulate surface expression of the CD4 receptor.

Authors:  Enrique Argañaraz; María José Cortés; Sydney Leibel; Juan Lama
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Signal peptide-binding drug as a selective inhibitor of co-translational protein translocation.

Authors:  Kurt Vermeire; Thomas W Bell; Victor Van Puyenbroeck; Anne Giraut; Sam Noppen; Sandra Liekens; Dominique Schols; Enno Hartmann; Kai-Uwe Kalies; Mark Marsh
Journal:  PLoS Biol       Date:  2014-12-02       Impact factor: 8.029

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.